BMS’s Bladder Cancer Program Sees Change In Fortunes With Opdivo Substudy Win

 
• By Alaric DeArment
  
Bristol Myers Squibb announced topline results from a substudy of the CheckMate-901 trial • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D